RenovoRx, Inc.
https://renovorx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RenovoRx, Inc.
In Times Of Adversity, Surgical Robot Developers Must Remain Sharp
Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Finance Watch: Prepare For September IPOs To Rebound From August Slowdown
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Infusion Therapy Equipment and Supplies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice